Immunosuppressive

Category

Roche Confirms Tocilizumab (Actemra®) Failed to Meet Endpoints in the Phase 3 COVACTA Study Involving COVID-19 Associated Pneumonia

TrialSite recently suggested based on unfolding study results that repurposed IL-6 inhibitors, such as Roche’s Actemra®/ReActemtra® (tocilizumab), may not work to treat patients infected with COVID-19. TrialSite pointed to the results of an Italian study as a...

Pin It on Pinterest